BioDrugs

, Volume 15, Issue 4, pp 225–238

Combination Therapy with Interferon-α and Ribavirin for Hepatitis C

Practical Treatment Issues
Therapy in Practice

DOI: 10.2165/00063030-200115040-00003

Cite this article as:
Collier, J. & Chapman, R. BioDrugs (2001) 15: 225. doi:10.2165/00063030-200115040-00003

Abstract

Combination therapy with ribavirin and interferon (IFN)-α for 6 to 12 months is currently the treatment of choice for chronic hepatitis C infection. The overall sustained response rate to treatment, defined as loss of hepatitis C virus (HCV) from serum 6 months after completion of treatment, is 40%. The indications for treatment are serum HCV RNA positivity, abnormal serum transaminases and the presence of portal fibrosis and/or moderate/severe inflammation.

Response rates are lower in genotype 1 than in genotype 2 or 3 and in the presence of a high viral load. Anaemia is the most common adverse event and is due to ribavirin; neuropsychiatric adverse effects due to IFNα lead to premature cessation of therapy in 10 to 20% of patients.

The current recommended dose of interferon is 3MU given subcutaneously 3 times a week. However, it is likely that longer-acting pegylated interferons, which may be more effective and can be administered once weekly, will in the future replace currently used IFNα.

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Department of Gastroenterology Level 3John Radcliffe HospitalOxfordEngland

Personalised recommendations